Company intelligence / Profile preview

AJNA BioSciences

Littleton, Colorado, United Statestheajnaoffensive.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company’s lead candidate AJA001 completed a Phase 1 single and multiple ascending dose trial demonstrating safety and tolerability in ASD patients. The formulation was optimized for ASD presentation. Results were presented at the American College of Neuropsychopharmacology in December 2024.[3]

Therapeutic areas: Psychiatry
Modalities: Botanical drugs (multi-cannabinoid botanical drug products)Plant-derived pharmaceuticals[1][3]Fungi-derived pharmaceuticals[3]
Industry: Biotech

Drug pipeline

4 assets

AJA004

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Charlotte's Web – joint venture partner via DeFloria for cannabinoid-based therapies.[3]

Beyond the preview

Go deeper on AJNA BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AJNA BioSciences.

Explore the full profile